Overview
Retatrutide is an investigational triple receptor agonist studied for its effects on metabolic regulation, body composition and glycemic control in preclinical and Phase-2 clinical research.
Mechanism of action
Simultaneous agonism of GLP-1, GIP and glucagon receptors modulates satiety, gastric emptying and hepatic glucose output while raising basal energy expenditure — a mechanistic combination not previously available in a single molecule.
Research summary
Phase-2 data (Jastreboff et al., NEJM 2023) reported dose-dependent body-weight reduction of up to 24% over 48 weeks alongside improvements in HbA1c and lipid markers in adult participants.
Research applications
- Obesity and body-composition research
- Type-2 diabetes and glucose-handling studies
- Cardiometabolic risk-factor research
Typical research dosing
| Period | Dose | Units (U-100) |
|---|---|---|
| Week 1–4 | 2 mg | 15 units |
| Week 5–8 | 4 mg | 30 units |
| Week 9–12 | 6 mg | 45 units |
| Week 13+ | 8 mg | 60 units |
Reconstitution & storage
Supplied as pre-filled FlexPen at 40 mg. No reconstitution required for pen format. Store refrigerated between doses.
Safety
For laboratory research use only. Not for human or veterinary use. Not FDA-approved for disease treatment.
References
- Jastreboff AM et al. NEJM 2023;389:514-526
- Rosenstock J et al. Lancet 2023;402:529-544
For research use only. Not for human or veterinary consumption. Not FDA-approved for the treatment or prevention of any disease.